Emerging Competition Issues Involving Follow-On Biologics
First published in Antitrust Magazine
Darren Tucker joined V&E’s global antitrust practice as a partner in January 2018. Arriving from Morgan Lewis & Bockius LLP, he brings valuable insights to clients regarding competition enforcement and policy issues.
In this article Tucker examines the ways in which pharmaceutical firms have allegedly delayed product entry in violation of the antitrust laws and whether this conduct is likely to occur in the context of biologics and how the antitrust analysis of this conduct may differ for biologics.
Key Contacts
Related Insights
- Insight
Previously published on Lexis Nexis – A Practical Guidance
July 22, 2021 - Insight
V&E Antitrust Update
July 16, 2021
This information is provided by Vinson & Elkins LLP for educational and informational purposes only and is not intended, nor should it be construed, as legal advice.